Peptide YY (PYY) belongs to the neuropeptide Y (NPY) family, which also includes the pancreatic polypeptide (PP) and NPY. PYY is secreted by the intestinal L cells, being present in the blood stream in two active forms capable of crossing the blood brain barrier, PYY (1-36) and its cleavage product, PYY (3-36). PYY is a selective agonist for the Y2 receptor (Y2R) and these receptors are abundant in the hippocampus. Here we investigated the mechanisms by which PYY (3-36) regulates intracellular Ca concentrations ([Ca]) in hippocampal neurons by employing a calcium imaging technique in hippocampal cultures. Alterations in [Ca] were detected by changes in the Fluo-4 AM reagent emission. PYY (3-36) significantly increased [Ca] from the concentration of 10M as compared to the controls (infusion of HEPES-buffered solution (HBS) solution alone). The PYY (3-36)-increase in [Ca] remained unchanged even in Ca-free extracellular solutions. Sarcoplasmic/endoplasmic reticulum Ca-ATPase pump (SERCA pump) inhibition partially prevent the PYY (3-36)-increase of [Ca] and inositol 1,4,5-triphosphate receptor (IP3R) inhibition also decreased the PYY (3-36)-increase of [Ca]. Taken together, our data strongly suggest that PYY (3-36) mobilizes calcium from the neuronal endoplasmic reticulum (ER) stores towards the cytoplasm. Next, we showed that PYY (3-36) inhibited high K-induced increases of [Ca], suggesting that PYY (3-36) could also act by activating G-protein coupled inwardly rectifying potassium K channels. Finally, the co-infusion of the Y2 receptor (Y2R) antagonist BIIE0246 with PYY (3-36) abolished the [Ca] increase induced by the peptide, suggesting that PYY (3-36)-induced [Ca] increase in hippocampal neurons occurs via Y2Rs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.npep.2017.11.003 | DOI Listing |
Glucagon-like peptide-1 receptor (GLP-1R) and neuropeptide Y receptors (NPYRs) are expressed in reproductive tissues contributing to the regulation of gonadal function. This exploratory study examines the potential impact of their modulation by assessing the effects of exendin-4 (Ex-4) and peptide YY (PYY) (3-36) on endocrine ovaries and adrenals in high-fat diet (HFD) mice. Ex-4 and PYY(3-36) reduced blood glucose and energy intake, with no effects on body weight.
View Article and Find Full Text PDFChemistry
December 2024
Department of Chemistry, University of Copenhagen, Thorvaldsensvej 40, DK-1871, Frederiksberg, Denmark.
Herein, we describe the design and synthesis of 16 neo-glycolipids that are potential permeation enhancers for oral drug delivery of peptide therapeutics. These amphiphilic neo-glycolipids are composed of fatty acids and various carbohydrates (d-glucose, lactose, cellobiose, maltose) via an oxime linker. The ability of the synthesized neo-glycolipids to enhance permeation of fluorescein-labelled dextran (4 kDa) or H-mannitol across intestinal epithelium was investigated in vitro using monolayers of human epithelial Caco-2 cells.
View Article and Find Full Text PDFBiomedicines
August 2024
Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece.
The human reward network consists of interconnected brain regions that process stimuli associated with satisfaction and modulate pleasure-seeking behaviors. Impairments in reward processing have been implicated in several medical and psychiatric conditions, and there is a growing interest in disentangling the underlying pathophysiological mechanisms. The brain-gut axis plays a regulatory role in several higher-order neurophysiological pathways, including reward processing.
View Article and Find Full Text PDFHeliyon
June 2024
Translational Medicine, Global Translation, Novo Nordisk A/S, 2760 Måløv, Denmark.
Objective: Co-treatment with long acting PYY and the GLP-1 receptor agonists has potential as an efficient obesity treatment. This study investigates whether the mechanisms behind additive reduction of food intake and weight loss depends on complementary effects in brain areas regulating food intake and if restoration of leptin sensitivity is involved.
Methods: Diet-induced obese (DIO) mice were co-treated with PYY(3-36) and exendin-4 (Ex4, GLP-1R agonist) for 14 days using minipumps.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!